LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Akcijų sąrašas・Heron Therapeutics Inc

Heron Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

0.45 7.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.42

Max

0.47

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M -8.1M
Pardavimai	-5.9M 35M
Pelnas, tenkantis vienai akcijai	-0.04
Pelno marža	-23.367
Darbuotojai	128
EBITDA	-4M -4.8M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+365.12% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-74M 157M
Ankstesnė atidarymo kaina	-6.69
Ankstesnė uždarymo kaina	0.45

Naujienos nuotaikos

By Acuity

70%

30%

292 / 344 reitingas Healthcare

Heron Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-05 19:20; UTC

Pagrindinės rinkos jėgos

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026-06-07 23:46; UTC

Rinkos pokalbiai

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

2026-06-07 23:36; UTC

Rinkos pokalbiai

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

2026-06-07 18:00; UTC

Uždarbis

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

2026-06-06 12:40; UTC

Įsigijimai, susijungimai, perėmimai

Correction to Texas Billionaires Article America's Resort -- WSJ

2026-06-06 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-06 08:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-06 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-06 00:14; UTC

Įsigijimai, susijungimai, perėmimai

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

2026-06-05 21:27; UTC

Uždarbis

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026-06-05 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026-06-05 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026-06-05 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Hog Futures Tumble to Close Week -- Market Talk

2026-06-05 19:10; UTC

Rinkos pokalbiai

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026-06-05 19:03; UTC

Rinkos pokalbiai

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026-06-05 18:59; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026-06-05 18:47; UTC

Rinkos pokalbiai

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026-06-05 18:34; UTC

Rinkos pokalbiai

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026-06-05 18:33; UTC

Įsigijimai, susijungimai, perėmimai

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026-06-05 17:50; UTC

Uždarbis

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026-06-05 17:27; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026-06-05 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-05 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Heron Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

365.12% į viršų

12 mėnesių prognozė

Vidutinis 2 USD 365.12%

Aukščiausias 2 USD

Žemiausias 2 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Heron Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Heron Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

292 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.